RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial
1. 系统已在2026-03-31 16:36:30对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
GL Bakris, M Saxena, A Gupta, F Chalhoub, J Lee…
Jama, 2024
jamanetwork.com
Importance Angiotensinogen is the most upstream precursor of the renin–angiotensin–aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis. Objective To evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. Design, Setting, and Participants This phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries …
